+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Premature Rupture Of Membranes Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 119 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294580
The premature rupture of membranes testing market size is expected to grow from USD 3.49 billion in 2026 to USD 3.75 billion in 2027 and is forecast to reach USD 5.37 billion by 2032 at 7.45% CAGR over 2027-2032. This report is Segmented by Test Method (Biochemical, Nitrazine, Ferning, Pooling, Amnio-Dye, and Ultrasound), Product Format (Rapid Kits, Strips, Reagents, Instruments, and QC Materials), Sample Type (Vaginal Secretions, Cervicovaginal Swabs, Amniotic Fluid, and Cervical Mucus), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecast in Value (USD).

Global Premature Rupture Of Membranes Testing Market Trends and Insights

Rising Incidence of Preterm Birth and PROM Sustains Structural Demand

Preterm birth remains a persistent global maternal and newborn health challenge, with 1 in 10 babies born before 37 weeks of gestation. The premature rupture of membranes testing market therefore benefits from an enduring clinical need for dependable assessment during pregnancies at risk of early delivery. South Asia and Sub-Saharan Africa carry a substantial preterm birth burden, which gives greater importance to accessible maternal diagnostic services. This concentration means that expanded access to prenatal and obstetric services in high-burden countries can translate into greater test volumes. The lack of a measurable decline in global preterm birth over the past decade also indicates that diagnostics will remain relevant even as preventive and therapeutic approaches advance.

Wider Adoption of Biomarker-Based PROM Tests Displaces Conventional Methods

Biomarker assays based on IGFBP-1 and PAMG-1 are gaining use when conventional examination or pH-based methods leave uncertainty. A 2025 study across 19 Indonesian centers reported 100% sensitivity for an IGFBP-1 immunoassay, compared with 75% for nitrazine testing, in the evaluated sample. A separate Kenyan hospital study reported 98% sensitivity and 98% specificity for the NADAL PROM test. The premature rupture of membranes testing market is responding to the operational benefit of tests that can be used without a speculum examination in appropriate care settings. Product uptake will remain dependent on clinical protocols that position biomarker results alongside, rather than apart from, clinical assessment.

High Cost of Advanced Immunoassay Tests Constrains Uptake in Price-Sensitive Markets

Advanced immunoassays can face adoption limits when their cost exceeds local procurement budgets or patient affordability. This issue is more acute in lower-resource settings, where national guidelines and reimbursement arrangements may not support routine use. The premature rupture of membranes testing market can therefore see different product mixes across public hospitals, private clinics, and reference laboratories. In the United States, coverage policies may narrow the use of some assays when payers judge the available evidence insufficient. Simply Healthcare Plans classified cervicovaginal PAMG-1 testing as not medically necessary in its 2025 policy, illustrating this reimbursement risk.

Other drivers and restraints analyzed in the detailed report include:

  1. Growing Demand for Rapid Point-of-Care Diagnosis
  2. Expansion of Prenatal and Maternal Healthcare Access Opens High-Volume Emerging Markets
  3. False-Positive and False-Negative Results Erode Clinical Confidence and Limit Guideline Adoption

Segment Analysis

Biochemical tests held 54.5% of the premature rupture of membranes testing market size in 2026. Their position reflects the use of PAMG-1 and IGFBP-1 assays in hospital triage, where clinicians need support in cases with uncertain membrane status. These tests address limitations of conventional nitrazine, ferning, and pooling methods that can be affected by sample conditions or unclear presentation. The clinical role is strongest where an immunoassay result is reviewed together with patient history and physical examination. The premature rupture of membranes testing market continues to favor methods that fit existing obstetric protocols without creating additional workflow steps.

Ultrasound tests are projected to record a 9.6% CAGR through 2032. Ultrasound can support the broader assessment of pregnancy risk and may guide the decision to use further diagnostic testing. It does not replace every biochemical method, because the tests answer different clinical questions. The segment gains from expanding maternal imaging capacity and the use of structured prenatal monitoring in hospitals and specialty clinics. Conventional methods are likely to retain a role in lower-resource facilities and in situations where they remain clinically suitable.

Rapid test kits accounted for 58.7% of the premature rupture of membranes testing market size in 2026. Their lead reflects the need for results during labor and delivery triage, when clinicians must make timely decisions about treatment, observation, and referral. A 2025 study of an iGFBP-1 rapid test cassette reported 98% sensitivity, 97.7% specificity, and 97.8% accuracy in the evaluated specimens. Test strips and cassettes remain closely related formats, with procurement and workflow preferences influencing the choice. Reader systems can also create recurring demand for compatible consumables and quality-control materials.

Reagents and extraction buffers are projected to expand at a 9.9% CAGR through 2032. This pattern points to increased testing through diagnostic laboratories and hospital reference laboratories rather than only at the bedside. Replenishment demand can give suppliers more predictable procurement cycles when laboratories process higher sample volumes. Integrated offerings that combine reagents, quality controls, readers, and connectivity features may have an advantage in institutional contracts. ISO 15189 accreditation requirements and CLIA quality standards also support attention to analytical control in laboratory-based testing.

Complete Report Scope:

  • By Test Method
    • Biochemical Tests
      • PAMG-1 Immunoassay
      • IGFBP-1 Test
      • Combined AFP and IGFBP-1 Test
      • Fetal Fibronectin Test
    • Nitrazine Test
    • Ferning Test
    • Pooling Test
    • Amnio-Dye Test
    • Ultrasound Test
  • By Product Format
    • Rapid Test Kits
    • Test Strips and Cassettes
    • Reagents and Extraction Buffers
    • Instruments and Readers
    • Quality-Control Materials
  • By Sample Type
    • Vaginal Secretions
    • Cervicovaginal Swabs
    • Amniotic Fluid
    • Cervical Mucus
  • By End User
    • Hospitals
    • Diagnostic Laboratories
    • Maternity Clinics and Birthing Centers
    • Obstetric and Gynecology Clinics
    • Other End Users
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 42.7% share in 2026. The region benefits from organized obstetric services, access to regulated diagnostic products, and clinical protocols that support prompt assessment when membrane rupture is suspected. The United States remains an important revenue base because it combines a significant preterm birth burden with established obstetric care infrastructure. ACOG’s 2025 advisory on previable and periviable PPROM reinforces the importance of timely diagnosis before counseling and treatment decisions. FDA regulatory review and payer coverage policies influence which tests can achieve broader clinical use. The 2025 Simply Healthcare Plans policy illustrates how reimbursement decisions can constrain the routine use of PAMG-1 testing.

The Asia-Pacific premature rupture of membranes testing market is projected to grow at an 8.5% CAGR through 2032. The region combines a large preterm birth burden with a rising need for accessible maternal diagnostics. South Asia’s substantial preterm birth burden supports demand for earlier and more accessible maternal assessment pathways. BGI Genomics introduced its LUM + fFN dual-biomarker rapid test in September 2026, providing a locally developed, 10-minute instrument-free option for preterm birth risk assessment. Investments in imaging, hospital capacity, and prenatal referral networks can support broader diagnostic access across the region. Japan and South Korea remain higher-value settings where adoption is shaped by established care systems and technology use. Regulatory compliance, provider training, and reimbursement will determine how rapidly new formats move from launch to routine care.

Europe is shaped by CE-IVD requirements and national health service protocols, which place compliance factors at the center of product adoption. The region’s hospitals and laboratories can support established biomarker testing, but suppliers must demonstrate clinical utility and fit local reimbursement requirements. In the Middle East and Africa, public health investment in Gulf Cooperation Council countries supports higher-value diagnostics, while South Africa remains an important sub-Saharan adoption base. The Gates Foundation’s 2025 commitment for AI-assisted ultrasound diagnostics in Nigeria, Ethiopia, and India demonstrates the focus on expanding maternal diagnostic capacity in underserved settings. South America, led by Brazil, has private-sector interest in rapid PROM testing, although public procurement limitations can slow wider adoption. The overall testing opportunity across these mixed geographies will be shaped by whether diagnostic access develops alongside care pathways that can act on the result. Manufacturers that offer simple collection methods, training, and evidence suited to public procurement will have a practical advantage.



List of Companies Covered in this Report:

  1. Abbott Laboratories
  2. QIAGEN
  3. Hologic
  4. The Cooper Companies
  5. Medix Biochemica
  6. BIOSYNEX S.A.
  7. Clinical Innovations
  8. Sera Prognostics, Inc.
  9. NX Prenatal
  10. IQ Products
  11. Roche
  12. Siemens Healthineers
  13. Thermo Fisher Scientific
  14. Beckton Dickinson
  15. QuidelOrtho
  16. Sekisui Diagnostics
  17. Bio-Rad Laboratories
  18. PerkinElmer
  19. Acon Laboratories

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Preterm Birth and PROM
4.2.2 Wider Adoption of Biomarker-Based PROM Tests
4.2.3 Growing Demand for Rapid Point-of-Care Diagnosis
4.2.4 Expansion of Prenatal and Maternal Healthcare Access
4.2.5 Blood-Tolerant Testing for Clinically Ambiguous Cases
4.2.6 Integration of PROM Results Into Obstetric Workflow Software
4.3 Market Restraints
4.3.1 High Cost of Advanced Immunoassay Tests
4.3.2 False-Positive and False-Negative Results
4.3.3 Uneven Reimbursement and Clinical Adoption
4.3.4 Pre-Analytical Interference From Blood and Vaginal Contaminants
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat Of New Entrants
4.7.2 Bargaining Power Of Buyers
4.7.3 Bargaining Power Of Suppliers
4.7.4 Threat Of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Test Method
5.1.1 Biochemical Tests
5.1.1.1 PAMG-1 Immunoassay
5.1.1.2 IGFBP-1 Test
5.1.1.3 Combined AFP and IGFBP-1 Test
5.1.1.4 Fetal Fibronectin Test
5.1.2 Nitrazine Test
5.1.3 Ferning Test
5.1.4 Pooling Test
5.1.5 Amnio-Dye Test
5.1.6 Ultrasound Test
5.2 By Product Format
5.2.1 Rapid Test Kits
5.2.2 Test Strips and Cassettes
5.2.3 Reagents and Extraction Buffers
5.2.4 Instruments and Readers
5.2.5 Quality-Control Materials
5.3 By Sample Type
5.3.1 Vaginal Secretions
5.3.2 Cervicovaginal Swabs
5.3.3 Amniotic Fluid
5.3.4 Cervical Mucus
5.4 By End User
5.4.1 Hospitals
5.4.2 Diagnostic Laboratories
5.4.3 Maternity Clinics and Birthing Centers
5.4.4 Obstetric and Gynecology Clinics
5.4.5 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
6.3.1 Abbott Laboratories
6.3.2 QIAGEN N.V.
6.3.3 Hologic, Inc.
6.3.4 CooperSurgical, Inc.
6.3.5 Medix Biochemica
6.3.6 BIOSYNEX S.A.
6.3.7 Clinical Innovations, LLC
6.3.8 Sera Prognostics, Inc.
6.3.9 NX Prenatal, Inc.
6.3.10 IQ Products
6.3.11 F. Hoffmann-La Roche Ltd
6.3.12 Siemens Healthineers AG
6.3.13 Thermo Fisher Scientific Inc.
6.3.14 Becton, Dickinson and Company
6.3.15 QuidelOrtho Corporation
6.3.16 Sekisui Diagnostics
6.3.17 Bio-Rad Laboratories, Inc.
6.3.18 PerkinElmer, Inc.
6.3.19 ACON Laboratories, Inc.
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • QIAGEN N.V.
  • Hologic, Inc.
  • CooperSurgical, Inc.
  • Medix Biochemica
  • BIOSYNEX S.A.
  • Clinical Innovations, LLC
  • Sera Prognostics, Inc.
  • NX Prenatal, Inc.
  • IQ Products
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • QuidelOrtho Corporation
  • Sekisui Diagnostics
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • ACON Laboratories, Inc.